

1 Expected endpoints from future
2 chikungunya vaccine trial sites informed
3 by serological data and modeling

4 **Quan Minh Tran¹, James Soda¹, Amir Siraj¹, Sean Moore¹, Hannah Clapham², T.
5 Alex Perkins¹**

6 ¹Department of Biological Sciences and Eck Institute for Global Health, University of
7 Notre Dame

8 ²Saw Swee Hock School of Public Health, National University of Singapore

9 *Corresponding author: qtran4@nd.edu

10 Present address: 100 Galvin Life Science Center, Notre Dame, IN 46556

11 Abstract

12 In recent decades, there has been an increased interest in developing a vaccine for
13 chikungunya. However, due to its unpredictable transmission, planning for a chikungunya
14 vaccine trial is challenging. To inform decision making on the selection of sites for a vaccine
15 efficacy trial, we developed a new framework for projecting the expected number of endpoint
16 events at a given site. In this framework, we first accounted for population immunity using
17 serological data collated from a systematic review and used it to estimate parameters related to
18 the timing and size of past outbreaks, as predicted by an SIR transmission model. Then, we
19 used that model to project the infection attack rate of a hypothetical future outbreak, in the event
20 that one were to occur at the time of a future trial. This informed projections of how many
21 endpoint events could be expected if a trial were to take place at that site. Our results suggest
22 that some sites may have sufficient transmission potential and susceptibility to support future
23 vaccine trials, in the event that an outbreak were to occur at those sites. In general, we
24 conclude that sites that have experienced outbreaks within the past 10 years may be poorer
25 targets for chikungunya vaccine efficacy trials in the near future. Our framework also generates
26 projections of the numbers of endpoint events by age, which could inform study participant
27 recruitment efforts.

28 Keywords: age-stratified serological data; hypothetical trial; mathematical model; phase-III
29 vaccine trial; selecting target population; site selection.

Abbreviations: CHIKV: Chikungunya virus; WHO: World Health Organization; IAR: Infection attack rate; SIR: susceptible-infected-recovered; IgG: immunoglobulin G; ELISA: enzyme-linked immunoassay; PRNT: plaque reduction neutralization tests; HI: hemagglutination inhibition.

30 Introduction

31 Chikungunya virus (CHIKV) is an arthropod-borne virus (arbovirus) that is transmitted by
32 mosquitoes. It is estimated that 1.3 billion people are currently living in areas at risk [1]. The first
33 documented global emergence of the virus started from Tanzania in 1952 and led to
34 subsequent outbreaks in sub-Saharan Africa, India, and Southeast Asia [2,3]. Though reports of
35 chikungunya cases diminished after its emergence in the 1950s, it has recently expanded to the
36 Americas and Europe [4–6]. The rapid spread and long-term effects of CHIKV [7–11] highlight
37 the need to find ways to improve on prevention of these outcomes. Like most viral infections,
38 there is no specific treatment for chikungunya, and patient care mostly relies on supportive
39 treatment. This emphasizes the need for prevention. Though vector control has been widely
40 used for arboviruses, it is difficult to employ effectively and often has only modest impacts [12–
41 14]. Thus, vaccination still remains the most promising prevention strategy when a safe and
42 efficacious vaccine is available.

43 Although no vaccines for chikungunya are currently licensed, there are several vaccine
44 candidates in development. The vaccines in phase I or phase II have shown promising results
45 with highly immunogenic reactions and minimal adverse effects [15]. Current vaccine
46 candidates in phase III relied on neutralizing antibody titers as the endpoints [16,17]. Since this
47 surrogate of protection is still debatable, additional vaccine trials that focus on clinical endpoint
48 events are still needed to truly assess the efficacy of these vaccine candidates. During public
49 health emergencies, vaccine candidates can be licensed before phase-III trials completed under
50 the World Health Organization (WHO) prequalification program. This has been the case for an
51 Ebola vaccine, and most recently for COVID-19 vaccines [18,19]. However, chikungunya has
52 not proceeded under this program. Thus, completing phase-III clinical trials is necessary for the
53 vaccine candidates to be licensed and become widely available for the public.

54 Vaccine development for CHIKV faces a serious obstacle when it comes to demonstrating
55 efficacy [15]. This owes to the fact that it is notoriously difficult to predict when and where
56 chikungunya outbreaks will occur due to the sporadic epidemiology of this disease. This means
57 that vaccine trials most likely need to be conducted during one or more outbreaks [20]. The
58 considerable logistical difficulties associated with conducting a trial during an outbreak place
59 even more importance on being prepared to carry out trials in locations where outbreaks may be
60 likely. Continuing outbreaks of chikungunya globally [21] offer encouragement about the
61 prospect of efficacy trials being possible, although current vaccine candidates have so far not
62 been able to leverage these outbreaks as opportunities for phase-III efficacy trials required for
63 licensure. Completion of a phase-III vaccine efficacy trial depends not just on a chikungunya
64 outbreak occurring somewhere, but in a particular population that can be enrolled and followed
65 during a trial. Advancements in the ability to appropriately select sites with a high probability of a
66 future outbreak are needed to speed up the evaluation of these vaccine candidates.


67 Mathematical modeling is playing an increasingly important role in vaccine trial planning in
68 general [22], including in the problem of site selection [23–25]. Site selection is a major
69 challenge for chikungunya vaccine efficacy trial planning due to its sporadic epidemiology. This
70 problem is traditionally solved with the help of epidemiological data to estimate recent incidence
71 of the proposed efficacy endpoint, such as reported cases of symptomatic disease. For
72 chikungunya, incidence is dynamic and not fixed over time. Moreover, it is likely that past
73 chikungunya outbreaks may have gone unreported or misdiagnosed [26]. Analysis of age-
74 stratified serological data offers one way to reconstruct recent patterns of CHIKV transmission
75 relevant to vaccine efficacy trial planning [27,28], but such analyses have only been performed
76 in a limited number of settings and have not been leveraged to directly inform vaccine efficacy
77 trial planning.

78 In this study, we use age-stratified serological data and mathematical modeling to project
79 vaccine trial endpoint incidence in the event of a future outbreak. Our approach consists of three
80 steps: 1) infer epidemic parameters from age-stratified serological data; 2) determine the
81 population immunity; and 3) project outbreak size and endpoint events if an outbreak were to
82 occur at the time of a vaccine trial. We first demonstrate our framework in a simulation study,
83 with the purpose of understanding the accuracy of our inferences when the true values of the
84 underlying parameters are known. We then apply this approach to 35 sites for which age-
85 stratified serological data were available, although we also propose this as a method that could
86 be applied to age-stratified serological data collected as part of pre-trial epidemiological studies.

87 **Materials and methods**

88 **Inform vaccine efficacy trial endpoints from serological data**

89 For a given location, we 1) estimate the basic reproduction number R_0 , the timing of past
90 outbreaks y , and average initial susceptible proportion before the first outbreak happened $S_0(0)$
91 from serological data, and 2) determine population immunity at the time of data collection.
92 Assuming a hypothetical outbreak happens during a vaccine efficacy trial in 2022, we then 3)
93 project the *IAR* of the outbreak and the number of endpoints expected among a given number of
94 subjects. This framework is summarized visually in Fig. 1. All of the code for this analysis was
95 written in the R language [29] and is available, along with all data required to reproduce this
96 study, in a GitHub repository [30].



97 **Figure 1. Framework to project the number of endpoint events in a future vaccine trial.**
 98 Our framework consists of three stages: 1) using serological data available before the vaccine
 99 trial, we can estimate the basic reproduction number R_0 , the average initial susceptible
 100 proportion before the first outbreak $S_0(0)$ (used to inform the susceptible proportion before the
 101 first outbreak $S_1(0)$ (Supplementary Text)), and the timing of past outbreaks y (panel A). 2) From
 102 the estimated parameters in A, we can derive the population immunity during the serological
 103 study at the site (panel B). 3) The population immunity at the time of a future vaccine trial can
 104 then be projected during the vaccine trial (panel C). In the event that an outbreak happens
 105 during that future trial, we project the infection attack rate (*IAR*) of the outbreak using the
 106 estimated R_0 and the projected population immunity. The number of expected endpoint events
 107 can be derived subsequently. Note: $S_1(0)$ and $S_2(0)$ are the susceptible proportion before the
 108 first and second outbreaks respectively; y_1 and y_2 are the timing of the first and second
 109 outbreaks; OB: outbreak
 110

111 1. Estimate R_0 , y , and $S_0(0)$ from age-stratified serological data

112 We assumed that the number positive p_i in each age group i follows a binomial distribution,
113 such that the log likelihood informed by serological data is

114
$$Likelihood = \sum_i [p_i \log(P_i) + (n_i - p_i) \log(1 - P_i)] \quad (1),$$

115 where n_i is the number of samples and P_i is the model's prediction of the proportion positive. We
116 can derive P_i from the age-stratified susceptibility in the population $S_{a,Y}$ in the year Y and age a
117 at which the data were collected, which equals

118
$$P_i = 1 - \sum_{a=a_i}^{a_u} S_{a,Y} pop_{a,Y} \quad (2),$$

119 where a_i and a_u are the lower bound and upper bound of age group i and $pop_{a,Y}$ is the proportion
120 of people in age group a at year Y . This age-specific proportion was derived from annual
121 population by age data from United Nations World Population Prospects [31], assuming the site
122 has the same age demographic as in country level.

123 Consistent with the sporadic nature of chikungunya outbreaks, we assume that the age-
124 stratified susceptibility $S_{a,Y}$ has a step-like shape, where each "step" of the seroprevalence curve
125 corresponds to an outbreak in the past [32]. The particular shape can be modeled in our
126 framework with an SIR model in which the years of past outbreaks are specified, along with the
127 basic reproduction number R_0 and the population susceptibility prior to the first outbreak within
128 the lifetime of the oldest study participants $S_0(0)$. The time between outbreaks corresponds to
129 the width of each step, while the susceptible-infected-recovered (SIR) model informs the
130 proportion immune following each outbreak, which corresponds to the height of each step (Fig.
131 1A). Details on how to derive $S_{a,Y}$ for given values of R_0 , the initial susceptible proportion, and
132 the timing of past outbreaks y are described in the Supplementary Text.

133 For each seroprevalence data set, we fitted five models, which differed in terms of the
134 number of historical outbreaks (1 to 5 outbreaks). We estimated the parameters R_0 , $S_0(0)$, and y
135 in a Bayesian framework, using the *BayesianTools* package [33]. We used the DREAMzs
136 algorithm, with one million iterations and a burn-in period of 500,000 iterations. The assumed
137 prior distributions for the parameters were

$$138 \quad R_0 \sim \text{Uniform}(1, 10)$$

$$139 \quad S_0(0) \sim \text{Uniform}(0, 1)$$

$$140 \quad y \sim \text{Uniform}(0, 99),$$

141 with the latter two being non-informative and the range for the R_0 prior being defined broadly
142 within the range of values generally observed for chikungunya [34]. Convergence was assessed
143 by calculating the potential scale reduction statistic \hat{R} using the *coda* package in R [35]. We
144 applied a post-processing reversible-jump Markov chain Monte Carlo algorithm from the *rjmc*
145 package [36] to derive ensemble weights of the five models for each data set. These weights
146 were then used to generate ensemble predictions.

147 2. Determine population seropositivity at the time of the study

148 From the estimates of R_0 , y , and $S_0(0)$, we can reconstruct the step-like shape of population
149 immunity in every age group at the time of the study. This reconstruction was done based on
150 the relationship between the basic reproduction number (R_0), the proportion susceptible in a
151 population before an outbreak $S(0)$, and the *IAR* over the course of an outbreak from a SIR
152 model as stated in step 1 and in the Supplementary Text.

153

154 3. *Number of expected endpoint events after a hypothetical outbreak in 2022*

155 For the next step, we projected the age-stratified positive proportion in the population to year
156 2022 to derive the positive proportion in the population before a hypothetical outbreak in 2022.
157 The age-stratified positive proportion was estimated individually from each of the five models
158 with different numbers of outbreaks.

159 Given the age-stratified positive proportion in the population in 2022 derived from model m ,
160 we can derive the infection attack rate for each model IAR_m if there was a hypothetical outbreak
161 in 2022 based on equation (1) in Supplement Text. The ensemble prediction of IAR can be
162 derived from the IAR_m for each model m and from the model weights estimated from the
163 RJMCMC algorithm in Step 1, according to

164
$$IAR = \sum_{m=1}^5 P(\text{Model}_m | \text{Data}) IAR_m. (3)$$

165 Consistent with the endpoint for chikungunya vaccine trials proposed by WHO [37], we
166 chose symptomatic cases as the endpoint for the hypothetical vaccine trials in 2022 that we
167 focused on in our analysis. The number of symptomatic cases among trial participants is
168 generated by multiplying the predicted IAR by the proportion of infections that result in
169 symptoms, which is sampled from a beta distribution with shape and scale parameters of 21.80
170 and 3.18, respectively. We derived this distribution from empirical estimates of the
171 asymptomatic proportion of CHIKV infections ranging from 3% to 28% [38–40], such that 95% of
172 samples would fall within this range.

173 Simulation study

174 *Model behavior across a range of parameter values*

175 To assess the behavior of our model, we calculated the *IAR* during a hypothetical outbreak
176 in 2022 across a range of parameter values. The range of R_0 values was chosen to be from 1 to
177 3, which is the typical R_0 values estimated from previous outbreaks [41]. We assume the study
178 was conducted in 2000 and that past outbreaks may have happened between 1900 to 2000 in
179 increments of ten years. We also explore how *IAR* will change if there is only one or multiple
180 past outbreaks. We expect that $S_0(0) < 1$ would have the same effect as an additional outbreak
181 before the first one, which is already covered by exploring how multiple outbreaks affect *IAR* as
182 just mentioned. Therefore, for simplicity, $S_0(0)$ was set to 1 so there was no immunity in the
183 population before the first outbreak.

184 *Performance of our inference method on simulated data*

185 To assess the performance of our model at estimating parameters, we applied our inference
186 method to simulated data from hypothetical serological studies with known parameters. These
187 hypothetical studies involved 2,000 simulated study participants, stratified into 20 age groups of
188 five years each. The outbreak times y were set to be 5, 45, and 85 years before the study time.
189 For these simulations, each outbreak had $R_0 = 1.5$ and $S_0(0) = 1$. These simulated datasets
190 were used to estimate back the parameters R_0 , y , and $S_0(0)$, which were then used to project
191 the *IAR* during a hypothetical outbreak in 2022. To assess the performance of our approach
192 when data is more limited, we also conducted a sensitivity analysis by changing the sample size
193 (only ten participants for each of 20 age groups) or the age bins (only five age groups of 20
194 participants each), but keeping everything else the same. The age distribution of Kenya [31]
195 was used in all of these simulations.

196 Applying to published serosurveys


197 After validating our method on simulated data, we applied it to published data, which were
198 obtained from a systematic review of CHIKV serological data [42]. Criteria for inclusion of
199 studies in this review were that a study should report data from immunoglobulin G (IgG)
200 enzyme-linked immunoassay (ELISA) test, plaque reduction neutralization tests (PRNT), or
201 hemagglutination inhibition (HI) on at least three age groups collected as part of a cross-sectional
202 study. We used estimates of population by age appropriate to the country and year of the study
203 as estimated by the United Nations World Population Prospects [31].

204 Results

205 Simulation study

206 *Model behavior across a range of parameter values*

207 To understand the relationships between the model's parameters and the predicted *IAR*, we
208 derived the possible values of *IAR* for a hypothetical outbreak in 2022, given a range of possible
209 values of R_0 and the timing of past outbreaks. In the case of a site with only one outbreak, we
210 observed that a longer time since the last outbreak and larger R_0 would be associated with a
211 higher *IAR* in 2022 (Fig. 2). When the time since the last outbreak was less than 10 years, the
212 *IAR* was less than 5%, regardless of the R_0 value.



213

214 **Figure 2. The relationship between R_0 , time from the last outbreak results in IAR in the**
215 **future outbreak in the model with only one outbreak.** The magnitude of the future IAR
216 generated is colored as shown in the legend. We observed that in the model with one outbreak,
217 higher R_0 and the further the time from the last outbreak will result in higher IAR .

218 When there have been multiple outbreaks at a site, the relationship between R_0 and IAR is
219 more complicated (Fig. S1, Fig. S2). We observed that as the time since the last outbreak and
220 the value of R_0 increase, the average values of IAR tend to increase (Fig. S1). This relationship
221 is similar to what we observed when we simulated data on a single outbreak. However, as the
222 time between the past outbreaks increases, the average values of IAR tend to decrease (Fig.
223 S2). This occurs because as the latest outbreaks are further away, a higher susceptible
224 proportion builds up between outbreaks. The subsequent outbreak then depletes this
225 susceptible proportion and leaves a smaller susceptible pool for the future hypothetical
226 outbreak. This will eventually lead to a decrease in the final IAR of the future hypothetical
227 outbreak. For example, if the most recent outbreak was in 2000, it would have been larger if the

228 outbreak before that had been in 1970 than if it had been in 1990. Thus, an outbreak in 2022
229 would be smaller because the most recent outbreak in 2000 had been larger.

230 *Performance of our inference method on simulated data*

231 To evaluate the performance of our model for estimating parameters and predicting *IAR*, we
232 applied it to simulated data on age-stratified seroprevalence with predefined parameter values
233 of $R_0 = 1.5$, $S_0(0) = 1$, and outbreak times of 5, 45, and 85 years before the serological study.
234 Our reconstruction of age-stratified seroprevalence, as expected, exhibited three step-like
235 increases corresponding to three past outbreaks (Fig. S4). The model probabilities for the five
236 models placed the most weight on the model with three outbreaks (94.8%, Fig. S3). Overall, the
237 uncertainty intervals of our estimates covered the true values well (Fig. S3). Furthermore, the
238 ensemble posterior prediction from the five models produced a good prediction to the age-
239 stratified serological data (Fig. S4).

240 We did assess our model performance on simulated data with more outbreaks (not
241 presented here) but found out that with $R_0 = 1.5$, more than three outbreaks within 100 years
242 depleted enough susceptibles that the final outbreak sizes became minimal and unable to be
243 inferred.

244 To assess how well the inference framework performs on less ideal data, we carried out a
245 sensitivity analysis in which we reduced the sample size or increased the size of the age bins
246 (Figs. S5-S8). Overall, this led to more uncertainty about the number of past outbreaks. That
247 notwithstanding, the estimates of R_0 , $S_0(0)$, and the timing of past outbreaks covered the
248 simulated values and fit the data reasonably well for models close to the correct number of past
249 outbreaks.

250 Since estimation of R_0 and the projection of the proportion susceptible at the time of a future
251 vaccine trial have the greatest influence on *IAR*, correctly identifying the number of past


252 outbreaks may not be strictly necessary if population susceptibility can still be ascertained. To
253 explore this possibility, we compared *IAR* values projected using true parameter values versus
254 parameter values inferred from different simulated data sets. When we used data sets with
255 smaller sample sizes and larger age bins, we found that the projected *IAR* values were
256 comparable to the true *IAR* values in terms of their central tendency, but more uncertain in
257 comparison to the more detailed simulated data set (Fig. S9).

258 Applying the model to published serosurveys

259 We applied our framework to age-stratified seroprevalence data identified through a
260 literature review [42]. In total, we used data from 18 studies consisting of 35 site-level datasets,
261 given that some studies reported data from multiple sites. A detailed description of each study is
262 available in the Supplementary Text and the colated data can be found in [dataset][30]. The
263 study sites were labeled alphabetically from A to R for convenience.

264 *Parameter estimates*

265 All of the model runs converged according to the potential scale reduction statistic \hat{R} .
266 Estimates of R_0 for all studies were within the range of 1 to 3 (Fig. 3), which is typical for
267 chikungunya [41]. Most sites had model weights for the one-outbreak model of >90%, showing
268 strong support for a one-outbreak model. However, several sites showed more support for a
269 model with two outbreaks (Fig. 3; sites A, H1, J, I2, I4, I5, I7, I8, L2), and one site in the
270 Philippines (M) appears to have had five outbreaks (model weight of five-outbreaks model is
271 99.5%). Estimates of $S_0(0)$ for most sites were highly uncertain, which is to be expected given
272 that most information in the data about susceptibility pertained to the period in which study
273 participants were alive, rather than before then.




274

275 **Figure 3. Parameter estimates for every study site.** Points and ranges in each row belong to
 276 one study site, representing the median and 95% CrI estimates of the parameters respectively.
 277 The first and second column show the ensemble distribution (blue) of $S_0(0)$ and R_0 from the five
 278 models. The third column shows the model weight for each of the five models. The fourth
 279 column is the timing of outbreak(s) estimated from the model that has the largest weight. The
 280 right labels are the ISO-3 code of the country where the site was conducted. Table S1 and Fig.
 281 S11 provide the code of the study site.

282


283 *Expected number of endpoint events*

284 Utilizing the estimated parameters, we computed the population immunity of the population
285 in 2022 before and after a hypothetical outbreak (Fig. S11), and subsequently projected the
286 expected number of endpoint events for every site. The numbers of endpoint events were
287 projected to be highly variable across sites. Only two sites (L5 and E) were projected to have
288 the 2.5 quantile of expected endpoint events higher than ten events per thousand study
289 participants (Fig. 4). These two sites either had higher R_0 (site E) or higher susceptibility in the
290 population before the hypothetical outbreak (site L5) (Fig. 4). When susceptibility was high,
291 increasing R_0 increased the expected number of events. However, when susceptibility was low,
292 a much higher R_0 value was required to result in an equivalent number of events, as observed
293 for site E (Fig. 4). A positive interaction between R_0 and susceptibility was also observed when
294 we inspected the relationship between the time since the last estimated outbreak and the
295 number of events (Fig. 5). With high enough R_0 , site E is expected to still obtain a higher
296 number of events despite more recently experiencing an outbreak.



297


298 **Figure 4. Relationship between R_0 , estimated number of endpoint events, and susceptible**
299 **proportion before a hypothetical outbreak in 2022 for every site.** Each point and range are
300 the median and 95% PPI for each site. The dashed lines represent studies that have at least
301 part of the 95% PPI below the value of 10 per 1,000 people. We annotated study sites that were
302 confidently projected to produce more endpoints than that in the event of an outbreak.



303

304 **Figure 5. Relationship between time since the last outbreak, estimated number of**
305 **endpoint events, and R_0 for every site.** Each point and range are the median and 95% PPI for
306 each site. The number of expected endpoints was plotted in \log_{10} scale. The dash linerange
307 represents studies that have the 95% PPI cross or below the value of 10 per 1000 people. We
308 annotated study sites that can confidently produce more than 10 endpoints per thousand
309 people.

310 Because historical outbreaks can affect the population immunity of older and younger
311 generations differently, we also stratified our results into two age groups—children (<18 years
312 old) and adults (≥ 18 years old)—and compared results between them. Adults generally have
313 experienced more outbreaks in the past than children; hence, susceptible proportions before
314 hypothetical outbreaks in 2022 are expected to be higher in children. This results in a higher
315 expected number of events in children than adults (Fig. 6).



316

317 **Figure 6. Comparing the number of expected events from a hypothetical outbreak in 2022**

318 **in different target groups: adults and children.** Each point and range are the median and

319 95% PPI for each site. The number of expected endpoints was plotted in \log_{10} scale. The dash

320 linerange are sites that have the 95% PPI of the number of endpoints crossing or below the

321 value of 10 per 1000 people. The size of each point refers to the magnitude of estimated R_0

322 from each site. We annotated study site that can produce more than 10 endpoints per thousand


323 people

324 Validation

325 We performed an additional analysis on site M at which the serological surveys were


326 conducted in multiple years (1973, 2012, and 2013). We used parameters R_0 and $S_0(0)$

327 estimated from the serological survey in 1973 to project seropositive proportions from every age
328 group following outbreaks in 2012 and 2013. We compared those projections with the positive
329 proportions of every age group estimated from fitting to data from all years. The same estimated
330 timings of past outbreaks after 1973 were used for both the predictions. We estimated R_0 from
331 the data in 1973 to be 1.22 (95% CrI: 1.13 - 1.33), which was lower than an estimate of 1.51
332 (95% CrI: 1.46 - 1.55) from the data from all years. Although the model run on 1973 data fit well
333 to the serological data on the year (Fig. 7A), the lower seropositive proportion predicted in 1973,
334 and most importantly the lower estimate of R_0 , led to a lower projection of the seropositive
335 proportion in older age groups in 2012 and 2013 (Fig. 7B, 7C). The model runs that included
336 data from all years resulted in a good fit for the serological data in 2012 and 2013 (Fig 7E and
337 7F). However, the higher R_0 estimate from this model run resulted in a poorer fit to the 1973
338 serological data (Fig. 7D). Consistent with these results, the *IAR* projections right after the five
339 previous outbreaks in the site using only the 1973 dataset were also lower (Fig. 8). This reflects
340 that there may be variability in the R_0 over time that our model does not capture.



341


342 **Figure 7. Posterior predictions of seropositivity for serosurveys conducted in 1973, 2012,**
343 **and 2013 at site M in the Philippines.** Panel A is the posterior prediction of 1973 serosurvey
344 using R_0 , $S_0(0)$, and the timing of past outbreaks estimated from the model with two outbreaks
345 but applying for the 1973 data only. Panel B and C are the datafit generated using R_0 , $S_0(0)$
346 from the 1973 data but timing of past outbreaks estimated from the data from all years. Panels
347 D, E, and F are the posterior prediction for every serosurvey using parameter estimates from
348 the model with five outbreaks for the data from all years. The points with their ranges show the
349 true values and 95% PPI of the positive proportion for every age group in the simulation data.
350 The red line and the gray area are the median and 95% PPI of ensemble positive proportion for
351 every age group estimated from the five models.



352

353 **Figure 8. Infection attack rate of the previous five outbreaks for the Philippines informed**
354 **by data from different combinations of years.** The boxplots are the *IAR* projected using
355 different data sets: the first two outbreaks that use estimates from 1973 data only (outbreak 1
356 and 2 in yellow), the three latest outbreaks that use estimates from 1973 data but with the timing
357 of past outbreaks estimated from the data that use all of the years (outbreak 3 to 5 in yellow),
358 and the five outbreaks that use estimates from the data from all years (green).

359 We also compared our estimates of the timing of past outbreaks to the timing of reported
360 outbreaks (Table S1) not used to inform our estimates (Fig. 9). Overall, most of our estimates
361 match the timing of reported outbreaks. However, the model performed less well for studies A
362 (Singapore) and K (Kerala, India). This is due to the fact that these studies only sampled
363 patients older than 18 years for study A and older than 14 years for study K. Missing information
364 from younger age groups may result in the model picking up the signal from unreported earlier
365 outbreaks instead. Interestingly, data sets from study R (Bolivia) and D (Benin) also apply to the
366 same age bins, yet our model still captured the timing of those reported outbreaks within its
367 credible intervals, though with a high uncertainty. This discrepancy is because these sites may
368 have had only one recent outbreak happen at any time between when the oldest of the missing
369 reported person was born and the time the study was conducted. Our model cannot pinpoint
370 exactly the timing of these outbreaks from these missing ranges, thus explaining the high
371 uncertainty in the estimates. The studies from I1 to I8 were conducted in different places in
372 Kenya; hence, there may be some variation in the estimates of the timing of past outbreaks.



373

374 **Figure 9. The timing of past outbreak estimates from our model as compared to the**
375 **timing of reported outbreaks.** For every study (coded as shown in Table S1 or Figure S11),
376 each point and range is the estimated median and 95% CrI of the timing of past outbreaks from
377 our model. The number of previous outbreaks are color-coded as in the legend. The diamond
378 shapes are the reported timing of outbreaks at each of those sites.

379 Discussion

380 In this study, we constructed a framework to make projections of expected endpoints for
381 future vaccine trials based on serological data for a candidate trial site. The framework employs
382 the historical transmission information imprinted in serological data to infer the susceptibility of
383 the population and a time-averaged R_0 from previous outbreaks. These quantities can then be
384 used to make projections of IAR for future outbreaks. We first applied this framework to

385 simulated data to assess its performance and then applied it to published serosurveys to make
386 inferences about hypothetical future trials. We propose that this framework is suitable for
387 planning a vaccine trial conducted during an outbreak and is independent of any particular trial
388 design, as all trials need endpoint events to be successful.

389 Our results suggest that, in most cases, outbreaks may be minimal if the time since the last
390 outbreak is 10 years or less, even at relatively high R_0 values. This is because it takes time for
391 the susceptible population to build up through births to a sufficient degree for an outbreak to
392 happen. This fits with previous reports of CHIKV outbreaks in some places, where it may take
393 10 or more years to re-emerge in a given population [43–45]. Similar expectations have been
394 described for Zika, another arbovirus with similar epidemiology [46].

395 When applying this framework to published serological data, our estimates of the timing of
396 past outbreaks generally agree with the timing of reported outbreaks at the same site. Although
397 estimates at some sites were not as good due to missing samples in younger age groups, this
398 can be noted and improved by collecting data for all ages in preparation for future vaccine trials.
399 Most of the sites we analyzed here appear to have experienced only a single outbreak within
400 the lifetimes of study participants, which is consistent with the idea that the occurrence of
401 chikungunya outbreaks is sporadic. We inferred that the site in Cebu City, Philippines appeared
402 to have experienced multiple outbreaks, a conclusion reached by a previous analysis using the
403 same data set but using a slightly different method [28].

404 Based on a WHO consultation for future phase-III chikungunya vaccine trials [37], future
405 clinical trials to assess vaccine efficacy need to be conducted across multiple sites and multiple
406 countries due to the unpredictable nature of CHIKV outbreaks [37]. These sites also need to be
407 chosen prospectively in a way that they accrue enough endpoint events that the trial has
408 enough power to detect a desired efficacy. Our framework can be used to support this objective
409 by offering a basis for determining which sites are expected to generate a larger number of

410 endpoint events, in the event that an outbreak occurs. Based on the aforementioned WHO
411 consultation, 62 endpoint events are needed to have 90% power to reject the null hypothesis
412 that the vaccine efficacy is less than 30% when the true efficacy is 70% [37]. Our analysis
413 identified two sites that alone could potentially accrue the required 62 endpoint events with
414 fewer than 6,200 study participants if an outbreak were to happen. One additional suggestion
415 from our framework is to potentially target enrollment on individuals who were born after past
416 outbreaks, given that they would be more likely to be susceptible.

417 Our approach addresses only one criterion for site selection: the expected incidence of
418 endpoint events. Conducting a vaccine trial during an outbreak poses other challenges that the
419 site selection process needs to take into account. A suitable site should also have trained
420 personnel, regulatory oversight, and testing facilities. There are also questions on how many
421 sites are needed and allocation of effort across sites. To answer this, a balance between the
422 expected incidence of endpoint events and limited resources is necessary. Many sites across
423 multiple countries also require considerable logistical effort to communicate among sites. These
424 challenges have been noted in a previous Ebola vaccine trial [47]. Ultimately, selecting suitable
425 sites for chikungunya vaccine efficacy trials is a multifaceted problem and the modeling
426 framework we proposed here can act as a screening tool so that the sites it recommends can be
427 further scrutinized according to other criteria, as well.

428 Our study has some limitations. For an arbovirus like CHIKV, heterogeneity plays an
429 important role in transmission, which could affect the relationship between R_0 and the *IAR*
430 [48,49]. However, estimation of R_0 based on observed *IAR* values is not the end goal of our
431 method. Rather, the goal here is to having a model that is capable of using past values of *IAR*
432 and an estimate of R_0 to predict future *IAR* values. Thus, the omission of heterogeneity may
433 lead to an inaccurate estimate of R_0 but does not necessarily compromise our main goal to
434 project future *IAR* [48,49]. Because we assume that R_0 for every outbreak is the same, our

435 framework will not perform as well in situations in which there is variation in transmission
436 between outbreaks [50]. This could partly explain why the R_0 estimates in the validation for the
437 Philippines site are different and lead to different projections of IAR . Analyzing seroprevalence
438 data from too far back could be a potential problem since we may miss recent outbreaks. This
439 could be remedied by conducting pilot seroprevalence studies, which is usually done before the
440 vaccine trial anyway. Another limitation of our analysis is that the symptomatic proportion is
441 sampled from a distribution derived from a widely cited asymptomatic proportion ranging 3 -
442 28% [38–40]. However, there is growing evidence that the asymptomatic proportion of CHIKV
443 may be lineage dependent [51]. This could easily be modified in our framework when the
444 circulating lineage in the selected site for the trial is known, or at least suspected. It is also worth
445 noting that our framework does not attempt to suggest when and where future outbreaks will
446 occur, but instead to assess how feasible a vaccine trial would be if an outbreak occurs.
447 Predicting the occurrence and timing of future chikungunya outbreaks remains a challenge and
448 is beyond the scope of this study.

449 In conclusion, we have established a comprehensive framework that can estimate the
450 number of expected endpoint events to inform future chikungunya vaccine efficacy trials using
451 age-stratified serological data. Our analysis shows that this framework is robust when applied to
452 simulated data but can also provide insights when applied to published data. In addition to
453 chikungunya, this framework could also be applied to other emerging viruses with similar
454 epidemiological dynamics.

455 Acknowledgements

456 Fundings: This research was supported by a Young Faculty Award from the Defense Advanced
457 Research Projects Agency (D16AP00114) and Start up grant from Saw Swee Hock School of
458 Public Health.

459 Conflict of interest

460 TAP receives consulting fees and research support from Emergent Biosolutions for work on
461 chikungunya vaccine trial planning. The study described in this manuscript was completed prior
462 to TAP's relationship with Emergent.

463 Reference

- 464 [1] Nsoesie EO, Kraemer MU, Golding N, Pigott DM, Brady OJ, Moyes CL, et al. Global
465 distribution and environmental suitability for chikungunya virus, 1952 to 2015.
466 *Eurosurveillance* 2016;21:30234. <https://doi.org/10.2807/1560-7917.ES.2016.21.20.30234>.
- 467 [2] Lumsden WH. An epidemic of virus disease in Southern Province, Tanganyika Territory, in
468 1952-53. II. General description and epidemiology. *Trans R Soc Trop Med Hyg*
469 1955;49:33–57. [https://doi.org/10.1016/0035-9203\(55\)90081-x](https://doi.org/10.1016/0035-9203(55)90081-x).
- 470 [3] Aikat BK, Konar NR, Banerjee G. Haemorrhagic fever in Calcutta area. *Indian J Med Res*
471 1964;52:660–75.
- 472 [4] Van Bortel W, Dorleans F, Rosine J, Bateau A, Rousset D, Matheus S, et al. Chikungunya
473 outbreak in the Caribbean region, December 2013 to March 2014, and the significance for
474 Europe. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull* 2014;19:20759.
475 <https://doi.org/10.2807/1560-7917.es2014.19.13.20759>.
- 476 [5] Yactayo S, Staples JE, Millot V, Cibrelus L, Ramon-Pardo P. Epidemiology of
477 Chikungunya in the Americas. *J Infect Dis* 2016;214:S441–5.
478 <https://doi.org/10.1093/infdis/jiw390>.
- 479 [6] Moro ML, Rezza G, Grilli E, Angelini R, Macini P, Spataro N, et al. Chikungunya Virus in
480 North-Eastern Italy: A Seroprevalence Survey. *Am J Trop Med Hyg* 2010;82:508–11.
481 <https://doi.org/10.4269/ajtmh.2010.09-0322>.

- 482 [7] Sissoko D, Malvy D, Ezzedine K, Renault P, Moschetti F, Ledrans M, et al. Post-Epidemic
483 Chikungunya Disease on Reunion Island: Course of Rheumatic Manifestations and
484 Associated Factors over a 15-Month Period. *PLoS Negl Trop Dis* 2009;3.
485 <https://doi.org/10.1371/journal.pntd.0000389>.
- 486 [8] Brighton SW, Prozesky OW, de la Harpe AL. Chikungunya virus infection. A retrospective
487 study of 107 cases. *South Afr Med J Suid-Afr Tydskr Vir Geneesk* 1983;63:313–5.
- 488 [9] Ed F, Jg M. Rheumatoid arthritic syndrome after chikungunya fever. *South Afr Med J Suid-*
489 *Afr Tydskr Vir Geneesk* 1979;56. <https://pubmed.ncbi.nlm.nih.gov/494034/> (accessed
490 September 15, 2020).
- 491 [10] Sp M, P V, R U, Ap S, Ss S, Sk R, et al. Clinical progression of chikungunya fever during
492 acute and chronic arthritic stages and the changes in joint morphology as revealed by
493 imaging. *Trans R Soc Trop Med Hyg* 2010;104.
494 <https://doi.org/10.1016/j.trstmh.2010.01.011>.
- 495 [11] Soumahoro M-K, Gérardin P, Boëlle P-Y, Perrau J, Fianu A, Pouchot J, et al. Impact of
496 Chikungunya virus infection on health status and quality of life: a retrospective cohort
497 study. *PloS One* 2009;4:e7800. <https://doi.org/10.1371/journal.pone.0007800>.
- 498 [12] Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness
499 or Evidence?: Systematic Review and Meta-analysis. *PLoS Negl Trop Dis*
500 2016;10:e0004551. <https://doi.org/10.1371/journal.pntd.0004551>.
- 501 [13] Ritchie SA, Staunton KM. Reflections from an old Queenslander: can rear and release
502 strategies be the next great era of vector control? *Proc R Soc B Biol Sci*
503 2019;286:20190973. <https://doi.org/10.1098/rspb.2019.0973>.
- 504 [14] Cavany SM, España G, Lloyd AL, Waller LA, Kitron U, Astete H, et al. Optimizing the
505 deployment of ultra-low volume and targeted indoor residual spraying for dengue outbreak
506 response. *PLOS Comput Biol* 2020;16:e1007743.
507 <https://doi.org/10.1371/journal.pcbi.1007743>.

- 508 [15] Rezza G, Weaver SC. Chikungunya as a paradigm for emerging viral diseases: Evaluating
509 disease impact and hurdles to vaccine development. *PLoS Negl Trop Dis* 2019;13:1–12.
510 <https://doi.org/10.1371/journal.pntd.0006919>.
- 511 [16] Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya
512 Vaccine Candidate – Valneva n.d. [https://valneva.com/press-release/valneva-successfully-](https://valneva.com/press-release/valneva-successfully-completes-pivotal-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate/)
513 [completes-pivotal-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate/](https://valneva.com/press-release/valneva-successfully-completes-pivotal-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate/) (accessed
514 March 10, 2022).
- 515 [17] Emergent BioSolutions. A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of
516 the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents.
517 clinicaltrials.gov; 2021.
- 518 [18] World Health Organization. Emergency Use Listing Procedure. 2020.
- 519 [19] World Health Organization. WHO Operational Tool for efficient and effective lot release of
520 SARS-CoV-2 (Covid-19) vaccines 2021.
521 [https://extranet.who.int/pqweb/sites/default/files/documents/WHO_OperationalTool_Efficie](https://extranet.who.int/pqweb/sites/default/files/documents/WHO_OperationalTool_EfficientLotRelease_v20Jan2021.pdf)
522 [ntLotRelease_v20Jan2021.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/WHO_OperationalTool_EfficientLotRelease_v20Jan2021.pdf) (accessed March 9, 2022).
- 523 [20] Dean NE, Gsell P-S, Brookmeyer R, Gruttola VD, Donnelly CA, Halloran ME, et al.
524 Considerations for the design of vaccine efficacy trials during public health emergencies.
525 *Sci Transl Med* 2019;11. <https://doi.org/10.1126/scitranslmed.aat0360>.
- 526 [21] Bettis AA, Jackson ML, Yoon I-K, Breugelmans JG, Goios A, Gubler DJ, et al. The global
527 epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform
528 the development and introduction of vaccines. *PLoS Negl Trop Dis* 2022;16:e0010069.
529 <https://doi.org/10.1371/journal.pntd.0010069>.
- 530 [22] Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, et al. Simulations
531 for designing and interpreting intervention trials in infectious diseases. *BMC Med*
532 2017;15:1–8. <https://doi.org/10.1186/s12916-017-0985-3>.
- 533 [23] Collaboration TZ, Asher J, Barker C, Chen G, Cummings D, Chinazzi M, et al. Preliminary

- 534 results of models to predict areas in the Americas with increased likelihood of Zika virus
535 transmission in 2017. *BioRxiv* 2017:187591. <https://doi.org/10.1101/187591>.
- 536 [24] Madewell ZJ, Piontti APY, Zhang Q, Burton N, Yang Y, Longini IM, et al. Using simulated
537 infectious disease outbreaks to guide the design of individually randomized vaccine trials.
538 *MedRxiv* 2021:2021.01.29.21250703. <https://doi.org/10.1101/2021.01.29.21250703>.
- 539 [25] Hitchings MDT, Grais RF, Lipsitch M. Using simulation to aid trial design: Ring-vaccination
540 trials. *PLoS Negl Trop Dis* 2017;11:e0005470.
541 <https://doi.org/10.1371/journal.pntd.0005470>.
- 542 [26] Oidtman RJ, España G, Perkins TA. Co-circulation and misdiagnosis led to
543 underestimation of the 2015–2017 Zika epidemic in the Americas. *PLoS Negl Trop Dis*
544 2021;15:e0009208. <https://doi.org/10.1371/journal.pntd.0009208>.
- 545 [27] Quan TM, Phuong HT, Vy NHT, Thanh NTL, Lien NTN, Hong TTK, et al. Evidence of
546 previous but not current transmission of chikungunya virus in southern and central
547 Vietnam: Results from a systematic review and a seroprevalence study in four locations.
548 *PLoS Negl Trop Dis* 2018;12:e0006246. <https://doi.org/10.1371/journal.pntd.0006246>.
- 549 [28] Salje H, Cauchemez S, Alera MT, Rodriguez-Barraquer I, Thaisomboonsuk B,
550 Srikiatkachorn A, et al. Reconstruction of 60 Years of Chikungunya Epidemiology in the
551 Philippines Demonstrates Episodic and Focal Transmission. *J Infect Dis* 2016;213:604–10.
552 <https://doi.org/10.1093/infdis/jiv470>.
- 553 [29] R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria:
554 2020.
- 555 [30] Github link. https://github.com/tranquanc123/CHIKV_endpoint_est.git
- 556 [31] Affairs UND of E and S. World Population Prospects: Data Booklet - 2015 Revision. United
557 Nations; 2016. <https://doi.org/10.18356/a3ba29cd57-en>.
- 558 [32] Cauchemez S, Hoze N, Cousien A, Nikolay B, ten Bosch Q. How Modelling Can Enhance
559 the Analysis of Imperfect Epidemic Data. *Trends Parasitol* 2019;35:369–79.

- 560 <https://doi.org/10.1016/j.pt.2019.01.009>.
- 561 [33] Florian Hartig, Francesco Minunno, Stefan Paul. BayesianTools: General-Purpose MCMC
562 and SMC Samplers and Tools for Bayesian Statistics. 2019.
- 563 [34] Perkins TA, Metcalf CJE, Grenfell BT, Tatem AJ. Estimating Drivers of Autochthonous
564 Transmission of Chikungunya Virus in its Invasion of the Americas. PLOS Curr Outbreaks
565 2015. <https://doi.org/10.1371/currents.outbreaks.a4c7b6ac10e0420b1788c9767946d1fc>.
- 566 [35] Martyn Plummer, Nicky Best, Kate Cowles, Karen Vines. CODA: Convergence Diagnosis
567 and Output Analysis for MCMC. 2006.
- 568 [36] Gelling N, Schofield MR, Barker RJ. R package rjmc : reversible jump MCMC using
569 post-processing. Aust N Z J Stat 2019;61:189–212. <https://doi.org/10.1111/anzs.12263>.
- 570 [37] World Health Organization. WHO consultation on Chikungunya vaccine evaluation.
571 Geneva, Switzerland: 2018.
- 572 [38] Chikungunya - Chapter 4 - 2020 Yellow Book | Travelers' Health | CDC n.d.
573 [https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/
574 chikungunya](https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/chikungunya) (accessed September 15, 2020).
- 575 [39] Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease
576 mechanisms, and prospective intervention strategies. J Clin Invest 2017;127:737–49.
577 <https://doi.org/10.1172/JCI84417>.
- 578 [40] Staples JE, Breiman RF, Powers AM. Chikungunya Fever: An Epidemiological Review of a
579 Re-Emerging Infectious Disease. Clin Infect Dis 2009;49:942–8.
580 <https://doi.org/10.1086/605496>.
- 581 [41] Liu Y, Lillepold K, Semenza JC, Tozan Y, Quam MBM, Rocklöv J. Reviewing estimates of
582 the basic reproduction number for dengue, Zika and chikungunya across global climate
583 zones. Environ Res 2020;182:109114. <https://doi.org/10.1016/j.envres.2020.109114>.
- 584 [42] Fritzell C, Rousset D, Adde A, Kazanji M, Van Kerkhove MD, Flamand C. Current
585 challenges and implications for dengue, chikungunya and Zika seroprevalence studies

- 586 worldwide: A scoping review. *PLoS Negl Trop Dis* 2018;12:1–29.
- 587 <https://doi.org/10.1371/journal.pntd.0006533>.
- 588 [43] Dudouet P, Gautret P, Larsen CS, Díaz-Menéndez M, Trigo E, von Sonnenburg F, et al.
- 589 Chikungunya resurgence in the Maldives and risk for importation via tourists to Europe in
- 590 2019–2020: A GeoSentinel case series. *Travel Med Infect Dis* 2020;36:101814.
- 591 <https://doi.org/10.1016/j.tmaid.2020.101814>.
- 592 [44] Konongoi SL, Nyunja A, Ofula V, Owaka S, Koka H, Koskei E, et al. Human and
- 593 entomologic investigations of chikungunya outbreak in Mandera, Northeastern Kenya,
- 594 2016. *PLOS ONE* 2018;13:e0205058. <https://doi.org/10.1371/journal.pone.0205058>.
- 595 [45] Laras K, Sukri NC, Larasati RP, Bangs MJ, Kosim R, Djauzi, et al. Tracking the re-
- 596 emergence of epidemic chikungunya virus in Indonesia. *Trans R Soc Trop Med Hyg*
- 597 2005;99:128–41. <https://doi.org/10.1016/j.trstmh.2004.03.013>.
- 598 [46] Counotte MJ, Althaus CL, Low N, Riou J. Impact of age-specific immunity on the timing
- 599 and burden of the next Zika virus outbreak. *PLoS Negl Trop Dis* 2019;13:e0007978.
- 600 <https://doi.org/10.1371/journal.pntd.0007978>.
- 601 [47] Kabineh AK, Carr W, Motevalli M, Legardy-Williams J, Vincent W, Mahon BE, et al.
- 602 Operationalizing International Regulatory Standards in a Limited-Resource Setting During
- 603 an Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)
- 604 Experience. *J Infect Dis* 2018;217:S56–9. <https://doi.org/10.1093/infdis/jiy111>.
- 605 [48] Miller JC. A Note on the Derivation of Epidemic Final Sizes. *Bull Math Biol* 2012;74:2125–
- 606 41. <https://doi.org/10.1007/s11538-012-9749-6>.
- 607 [49] Miller JC, Slim AC, Volz EM. Edge-based compartmental modelling for infectious disease
- 608 spread. *J R Soc Interface* 2012;9:890–906. <https://doi.org/10.1098/rsif.2011.0403>.
- 609 [50] Oidtman RJ, Lai S, Huang Z, Yang J, Siraj AS, Reiner RC, et al. Inter-annual variation in
- 610 seasonal dengue epidemics driven by multiple interacting factors in Guangzhou, China.
- 611 *Nat Commun* 2019;10:1148. <https://doi.org/10.1038/s41467-019-09035-x>.

- 612 [51] Carrillo FB, Collado D, Sanchez N, Ojeda S, Mercado BL, Burger-Calderon R, et al.
613 Epidemiological Evidence for Lineage-Specific Differences in the Risk of Inapparent
614 Chikungunya Virus Infection. J Virol 2019;93. <https://doi.org/10.1128/JVI.01622-18>.